<h4>Objective</h4>Sintilimab, a programmed cell death protein 1 (PD-1) inhibitor, is widely used in cancer immunotherapy, but its hematological toxicity profile in real-world settings remains incompletely understood. The gene discussed is PDCD1; the disease is cancer.